Prenatal maternal immune disruption and sex-dependent risk for psychoses

J. M Goldstein[1,2,3]*, S. Cherkerzian[1,2], L. J. Seidman[3,4], J.-A. L. Donatelli[5], A. G. Remington[1], M. T. Tsuang[6,7,8], M. Hornig[9,10] and S. L. Buka[5]

[1] *Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Boston, MA, USA;* [2] *Departments of Psychiatry and Medicine, Harvard Medical School, Boston, MA, USA;* [3] *Division of Psychiatric Neuroscience, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA;* [4] *Harvard Medical School, Department of Psychiatry, Massachusetts Mental Health Center; Division of Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA;* [5] *Department of Epidemiology, Brown University, Providence, RI, USA;* [6] *Beth Israel Deaconess Hospital, Department of Psychiatry, Division of Public Psychiatry, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA, USA;* [7] *Center for Behavioral Genomics, Department of Psychiatry; Institute for Genomic Medicine, University of California at San Diego, La Jolla, CA, USA;* [8] *Harvard Institute of Psychiatric Epidemiology and Genetics, Harvard School of Public Peath, Boston, MA, USA;* [9] *Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA;* [10] *Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA*

Background. Previous studies suggest that abnormalities in maternal immune activity during pregnancy alter the offspring's brain development and are associated with increased risk for schizophrenia (SCZ) dependent on sex.

Method. Using a nested case–control design and prospectively collected prenatal maternal sera from which interleukin (IL)-1β, IL-8, IL-6, tumor necrosis factor (TNF)-α and IL-10 were assayed, we investigated sex-dependent associations between these cytokines and 88 psychotic cases [SCZ=44; affective psychoses (AP)=44] and 100 healthy controls from a pregnancy cohort followed for >40 years. Analyses included sex-stratified non-parametric tests adjusted for multiple comparisons to screen cytokines associated with SCZ risk, followed by deviant subgroup analyses using generalized estimating equation (GEE) models.

Results. There were higher prenatal IL-6 levels among male SCZ than male controls, and lower TNF-α levels among female SCZ than female controls. The results were supported by deviant subgroup analyses with significantly more SCZ males with high IL-6 levels (>highest quartile) compared with controls [odd ratio $(OR)_{75}$=3.33, 95% confidence interval (CI) 1.13–9.82], and greater prevalence of low TNF-α levels (<lowest quartile) among SCZ females compared with their controls $(OR_{25}$=6.30, 95% CI 1.20–33.04) and SCZ males. Higher levels of IL-6 were only found among SCZ compared with AP cases. Lower TNF-α levels (non-significant) also characterized female AP cases *versus* controls, although the prevalence of the lowest levels was higher in SCZ than AP females (70% *v.* 40%), with no effect in SCZ or AP males.

Conclusions. The results underscore the importance of immunologic processes affecting fetal brain development and differential risk for psychoses depending on psychosis subtype and offspring sex.

Introduction

Epidemiologic and preclinical studies have suggested associations between maternal infection, prenatal exposure to inflammatory cytokines and risk for schizophrenia (SCZ) (McGrath & Murray, 2003; Brown & Derkits, 2010). Earlier studies investigated maternal immune function and later onset of SCZ in offspring using direct measures of maternal infection, such as

antibody titers in sera collected during pregnancy. Brown *et al.* (2004*a*, 2009) provided serologic evidence of elevated maternal antibodies to influenza virus and/or toxoplasmosis during the pregnancies of cases with psychoses *versus* controls. Our group (Buka *et al.* 2001*a*) and others (Brown & Derkits, 2010) reported that offspring of mothers with elevated immunoglobulin (Ig) G and IgM levels and antibodies to herpes simplex virus type 2 during pregnancy were at increased risk for SCZ and other psychoses. The diversity of microbes across these studies suggested that cytokines and other inflammatory markers generated in response to maternal obstetric conditions may function as a common pathway that alters the offspring's early brain

* Address for correspondence: Dr J. M. Goldstein, Brigham and Women's Hospital, One Brigham Circle, Division of Women's Health, 1620 Tremont Street, 3rd Floor, Boston, MA 02120, USA.

(Email: jill_goldstein@hms.harvard.edu)

development and increases risk for SCZ and other psychoses (Gilmore & Jarskog, 1997; Patterson, 2007; Brown & Derkits, 2010; Hornig, 2013).

In similar studies, our group (Buka *et al.* 2001*b*) and Brown *et al.* (2004*b*) reported significant associations of risk for SCZ and SCZ spectrum respectively with elevated tumor necrosis factor (TNF)-*α* and/or inter-leukin (IL)-8 levels in maternal serum collected during late pregnancy. Consistent with neuropathologic changes reported in SCZ, *in vitro* and *in vivo* animal studies have complemented these findings. Thus, rat neuronal cultures (human late second-trimester equivalent) exposed to IL-1*β*, IL-6 and TNF-*α* resulted in a dose-dependent reduction in dendritic length and number in the frontal cortex (Marx *et al.* 2001; Gilmore *et al.* 2004). Furthermore, multiple studies (Zuckerman & Weiner, 2003; Smith *et al.* 2007*a*,*b*) have noted a relationship between prenatal cytokine exposure and behavioral or brain abnormalities in the offspring. Peripheral induction of cytokines through administration of the innate immune activator and viral mimic polyinosinic:polycytidylic acid (poly I:C) was shown to alter latent inhibition (LI) in rodents, demonstrating post-pubertal emergence of LI dis-ruption and pronounced alterations in hippocampal morphology (Zuckerman & Weiner, 2003). This was consistent with demonstration of persistent hyperactiv-ity and hippocampal and cerebellar abnormalities in rodents subsequent to exposure to virus-induced, pro-inflammatory cytokine elevations during a period analogous to the early third trimester (Hornig *et al.* 1999). Taken together, these animal and human studies support the view that prenatal exposure to inflam-matory cytokines results in altered neurocellular devel-opment information processing deficits and increased SCZ risk.

Population-level studies investigating the neuro-behavioral consequences of gestational immune changes have examined the effects of obstetric con-ditions occurring during the second and third trime-sters of pregnancy, such as pre-eclampsia (Dalman *et al.* 1999; Eide *et al.* 2013). This is particularly relevant for studies of sex differences in the risk for psychosis, as this is a crucial period of the organizational effects of gonadal hormones on sexually differentiated brain development (Handa *et al.* 1994; Kawata, 1995; Tobet, 2002). In fact, previous studies linked conditions suggesting maternal immune disruption during preg-nancy (e.g. influenza, pre-eclampsia) to higher SCZ risk among male offspring (Dalman *et al.* 1999), explaining, in part, the higher risk of SCZ in males than females (Castle *et al.* 1993; O'Connell *et al.* 1997). For the past 25 years, we have been investigating the hypothesis that fetal disruptions during the middle to latter half of pregnancy will contribute to sex differences in risk for SCZ (Goldstein & Walder, 2006). IL-1*β*, IL-6, IL-8, TNF-*α* and IL-10 receptors are located in, among other regions, the hippocampus, ven-tromedial and paraventricular hypothalamic nuclei, amygdala and locus coeruleus (Harbuz *et al.* 1992; Schobitz *et al.* 1993; Szelenyi & Vizi, 2007), brain re-gions that are normally sexually dimorphic at the vol-ume level (Goldstein *et al.* 2001) or at the nuclei level in animals (Handa *et al.* 1994; Kawata, 1995; Tobet, 2002; Stratton *et al.* 2011) and are found to be abnormal in SCZ. These normally sexually dimorphic brain regions, implicated in the fetal hormonal programming of the brain (Seckl, 2001; Seckl & Walker, 2001), also co-localize with immune markers, suggesting that hor-monal–immune interactions play an important role in regulating the sex-dependent development of these key brain areas.

The current investigation used a nested case–control design and prospectively collected prenatal sera from a cohort followed from pregnancy to age 48 years to investigate the associations of the pro-inflammatory cytokines IL-1*β*, IL-6, IL-8, TNF-*α*, and the anti-inflammatory cytokine IL-10, with the sex-dependent risk for SCZ. We hypothesized that levels of these pro-inflammatory cytokines would be significantly higher among SCZ cases compared with controls whereas levels of the anti-inflammatory cytokine IL-10 would be lower, with the most significant effects among male offspring with SCZ.

Method

Participants were selected from 17741 pregnancies en-rolled between 1959 and 1966 into the Boston and Providence sites of the Collaborative Perinatal Project (CPP), also known as the New England Family Study (NEFS) (Goldstein *et al.* 2010, 2011; Seidman *et al.* 2013). The CPP of the National Institute of Neuro-logical and Communicative Disorders and Stroke was initiated over 40 years ago to prospectively investigate prenatal and familial antecedents of childhood neuro-psychiatric disorders by ascertaining 50000 preg-nancies and following offspring to age 7 (Niswander & Gordon, 1972). In a series of studies, we identified participants with psychoses among the original par-ents (Goldstein *et al.* 2010, 2011) and offspring now adults in their late 40s (Goldstein *et al.* 2010; Seidman *et al.* 2013).

As detailed in the online Supplementary material, through our ascertainment procedures we identified 200 offspring with possible, probable or definite psy-chotic and/or bipolar disorder. Of these, 114 had a DSM-IV major psychotic disorder; nine were deter-mined from medical charts alone; and the remainder completed diagnostic interviews (most with medical

charts as well). For the current study, we included only those subjects for whom third-trimester maternal sera were available. Diagnoses were grouped based on previous literature (Faraone & Tsuang, 1985; Kendler *et al.* 1985; Gottesman, 1991; Tsuang *et al.* 1993; Goldstein *et al.* 2010). The final sample included 44 with schizophrenia psychoses (40 SCZ; four with schizo-affective disorder – depressed type) and 44 with affective psychoses (AP: 21 bipolar disorder with psychosis; 15 schizo-affective disorder – bipolar type; eight with major depressive disorder with psychosis).

Controls were selected from families participating in a parallel high-risk study that identified original study parents with psychotic disorders and unaffected control parents (Goldstein *et al.* 2010, 2011). Controls were NEFS adult offspring for whom parents and grand-parents, along with the parents' siblings, were free of any known lifetime history of psychosis, bipolar, schizotypal, recurrent major depressive disorder, suicide attempts or psychiatric hospitalizations, as described previously (Goldstein *et al.* 2010). Siblings of the controls were also free of any lifetime history of psychosis or bipolar disorder. Although controls were free of any psychotic diagnoses, 59% (64 of 108) had some lifetime Axis I psychiatric diagnosis, the most common being substance abuse.

Human subjects approval was granted by Harvard University, Brown University, Partners Healthcare system and local psychiatric facilities. Written consent was obtained from all study participants interviewed, and subjects were compensated for participating.

Biological samples

From 1959 to 1966, maternal serum samples were collected approximately every 2 months from prenatal to delivery and stored at −20 °C at the National Institutes of Health (NIH) repository. We selected five immune molecules (IL-1β, IL-6, IL-8, TNF-α and IL-10) for assay because their associated receptors are located in highly sexually dimorphic brain regions in stress circuitry. Assays from the beginning of the third trimester were analyzed (measured in pg/ml), given that this time point is within the period of hormonal regulation of sexual brain differentiation, and the primary hypotheses in this study involved sex-dependent risk estimates. Sera samples were available for 88 cases and 100 controls. Missing data reflect 2% of draws that were not performed and absence of samples from the NIH repository or cracked vials obviating their use.

Maternal cytokine levels were assessed using a multiplexed, bead-based immunoassay (Milliplex™ human cytokine panel, MPXHCYTO-60 K, Millipore, USA) on a Luminex 3D™ detection platform

(Luminex Corporation, USA) (Vignali, 2000). Assay sensitivities ranged from 0.1 to 0.4 pg/ml. Twenty-five microliters of each serum sample were diluted 1:1 in Assay Buffer and run with six serial dilutions (3.2–10 000 pg/ml) of cytokine standards, two quality control and one normal serum standards on each 96-well plate (Martins, 2002). All samples, standards and controls were run in duplicate. Assays were completed according to the manufacturers' protocols, with overnight incubation at 4 °C on a shaker prior to detection of the mean fluorescence intensity (MFI) of analyte-specific immunoassay beads by Luminex 3D. Raw data (MFI) were captured using Luminex xPONENT™ software (v. 4.0.846.0) and concentrations of immune factors in each sample were interpolated from standard curves using a five-parameter, weighted, logistic regression curve equation in Milliplex Analyst™ (v. 3.5.5.0). Measurements below the lower limit of detection were excluded. For measurements at or above the upper limit of analyte detection, samples were assayed again at multiple serial dilutions using Assay Buffer to bring concentrations into a detectable range.

Statistical analyses

The pro-inflammatory cytokines included IL-1β, IL-8, IL-6 and TNF-α. Although IL-6 can also be anti-inflammatory, its impact has been considered pro-inflammatory in many contexts (Elenkov, 2008; Drexhage *et al.* 2010) and it was therefore categorized here as pro-inflammatory. The impact of IL-10, an anti-inflammatory cytokine, on psychosis risk was also examined. Cytokine data were positively skewed (skew > |0.8|) and thus natural log (ln) transformed to minimize departures from Gaussian distributions. With the exception of ln(TNF-α), the distributions of ln transformed variables were not skewed.

Sex-stratified analyses were conducted to test the impact of prenatal immune abnormalities on risk for SCZ, predicting that levels of cytokines would be higher among SCZ males *versus* controls using a two-step approach. We first screened the five cytokines to identify those for which levels differed between SCZ cases and controls by sex. Given the skew of the ln(TNF-α) distribution, and for consistency across all cytokines, group comparisons were conducted using non-parametric tests, primarily the Wilcoxon rank-sum test. If the two populations differed in spread (using the Ansari–Bradley test), the Kolmogorov–Smirnov test was used. Multiple comparisons for each screen set were adjusted using the 'step-up' procedure of Hochberg (1988).

Considering the limited statistical power, given our sample size, we used a liberal threshold of $p \leqslant 0.20$

when adjusting for multiple comparisons to improve sensitivity of the initial screen. For cytokines with a median difference that met this adjusted threshold, we conducted analyses based on deviant subgroups. For differences in which cases had higher levels of prenatal cytokines than controls, the deviant subgroup was created above the highest quartile (75th percentile) of the control ln transformed levels. For differences in which cases had lower levels of prenatal cytokines than controls, the deviant subgroup was created below the lowest quartile (25th percentile) of the control ln transformed levels. The frequency of subjects, by SCZ status, in the deviant subgroup was calculated and tested using χ^2 unless there were $\leqslant 5$ subjects in a cell, in which case Fisher's exact test was applied. Similar analyses were conducted for APs to determine specificity of the SCZ results. Adjusted odds ratios (ORs) from the deviant subgroup analyses were calculated using the generalized estimating equation (GEE) method, adjusted for intrafamilial correlation and demographic variables for which there were significant differences by SCZ and sex. For male-specific analyses, these variables were ethnicity, marital status and study site. There were no significant differences between female cases and controls on any of the potential confounding variables examined.

Results

As shown in Table 1 (for combined sex results, see Supplementary Table S1), subjects were primarily Caucasian, married and from Boston. Male cases included significantly more African-Americans ($\chi_2^2 = 9.49$, $p = 0.002$), single mothers ($\chi_3^2 = 6.77$, $p = 0.03$) and participants from Providence ($\chi_1^2 = 3.94$, $p < 0.05$) than controls. There were no significant differences between female cases and controls for any of the potential confounding variables examined.

Table 2 presents the sex-stratified non-parametric results of the cytokine assays for the SCZ and control subject groups (for combined sex results, see Supplementary Table S2). Median levels of IL-1β and IL-6 were higher among male SCZ cases than controls, significantly for IL-6 alone (2.81 pg/ml *v.* 1.06 pg/ml, $p_{Hochberg} = 0.05$). Median levels of TNF-α were similar among male cases and controls (3.74 pg/ml *v.* 3.73 pg/ml, $p_{Hochberg} = 0.78$). Among females, median levels of IL-1β, IL-8 and IL-6 were higher among subjects with SCZ compared with controls, but maternal prenatal levels of TNF-α were lower among SCZ *versus* controls (1.79 pg/ml *v.* 3.86 pg/ml, $p_{Hochberg} = 0.15$).

About two times the number of male SCZ subjects had IL-6 levels above the highest quartile than controls (47% *v.* 23%, Table 3a), with a 3.33 adjusted odds [95% (confidence interval (CI) 1.13–9.82] of having IL-6

levels above this threshold. Above the deviant threshold, female SCZ cases and their controls were similar in prevalence (33% *v.* 27%, Table 3a; for combined sex results, see Supplementary Table S3). The interaction between case status and sex for IL-6 was not significant ($Z = 1.43$, $p = 0.15$). In these analyses, there were no significant differences between AP cases and controls (Table 3b; for combined sex results, see Supplementary Table S3). For males and females, deviant levels of IL-6 were non-significantly elevated among SCZ cases compared with AP (OR 2.04 and 2.66 respectively; Table 4). In fact, given that ORs were of similar magnitudes in male and female SCZ subjects, combining both sexes resulted in a significantly higher likelihood of SCZ subjects being in the deviant subgroup of IL-6 compared with AP (OR 3.14, 95% CI 1.12–8.79, see Supplementary Table S3), suggesting that high levels of IL-6 may be specific to SCZ psychoses, but not dependent on sex.

Despite the small sample of SCZ females, it was among these females that low levels of TNF-α (values below the lowest quartile of the control distribution) were significantly more prevalent than among female controls (70% *v.* 23%, Fisher's exact, $p = 0.01$; see Table 3a) or SCZ males (70% *v.* 26%, Fisher's exact, $p = 0.02$, data not presented), with a trend toward a higher prevalence in female SCZ *versus* female APs (70% *v.* 40%, Fisher's exact, $p = 0.11$; see Table 4). The interaction between case status and sex for TNF-α was significant ($Z = 2.48$, $p = 0.01$).

Discussion

Among the five cytokines examined in this study, we found differences by SCZ case status for IL-6 and TNF-α. Exposure to high maternal levels of IL-6 was significantly more prevalent among SCZ cases than controls, particularly male SCZ cases. By contrast, and despite having a smaller female case sample size, the association of low levels of TNF-α to SCZ was specific for females, with low levels being significantly or marginally significantly more prevalent in female SCZ than in female controls, female APs or SCZ males. The differential findings by sex cannot be explained by sampling bias from age at follow-up, given that we ascertained subjects up to the age of 48 years, that is through the major risk period for SCZ.

Our findings suggest that prenatal exposure to different immune markers may differentially affect the development of psychoses, an effect that is dependent on psychosis type, offspring sex and the gestational timing of the serum draw. These factors may explain the inconsistency of our findings relative to those from earlier studies. Our earlier study in a small sample (Buka *et al.* 2001*b*) and the study by Brown *et al.*

Table 1. *Demographic information on the 188 subjects with third-trimester cytokine data from the schizophrenia (SCZ) case–control study stratified by sex*

	Psychosis (SCZ and AP)		Controls	
	Males ($n=53$)	Females ($n=35$)	Males ($n=48$)	Females ($n=52$)
Categorical variables[a], n (%)				
Ethnicity, mother				
Caucasian	41 (77.4)	28 (80.0)	47 (97.9)	46 (88.5)
African-American	12 (22.6)	7 (20.0)	1 (2.1)	4 (7.7)
Other	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.8)
Socio-economic status of origin, quartile				
Lowest	14 (26.4)	7 (20.0)	10 (20.8)	10 (19.2)
Lower middle	16 (30.2)	5 (14.3)	10 (20.8)	18 (34.6)
Upper middle	14 (26.4)	10 (28.6)	15 (31.3)	9 (17.3)
Highest	7 (13.2)	13 (37.1)	13 (27.1)	12 (23.1)
Missing	2 (3.8)	0 (0.0)	0 (0.0)	3 (5.8)
Marital status, mother				
Single	6 (11.3)	2 (5.7)	0 (0.0)	1 (1.9)
Married	47 (88.7)	32 (91.4)	47 (97.9)	48 (92.3)
Divorced	0 (0.0)	0 (0.0)	1 (2.1)	2 (3.8)
Separated	0 (0.0)	1 (2.9)	0 (0.0)	1 (1.9)
Season of birth				
Winter (December–February)	12 (22.6)	8 (22.9)	10 (20.8)	13 (25.0)
Spring (March–May)	14 (26.4)	10 (28.6)	17 (35.4)	10 (19.2)
Summer (June–August)	14 (26.4)	8 (22.9)	11 (22.9)	15 (28.8)
Fall (September–November)	13 (24.5)	9 (25.7)	10 (20.8)	14 (26.9)
Study site				
Boston	35 (66.0)	26 (74.3)	40 (83.3)	38 (73.1)
Providence	18 (34.0)	9 (25.7)	8 (16.7)	14 (26.9)
Continuous variables[b], mean (S.D.)				
Maternal variables				
Age (years)	26.0 (6.3)	25.1 (5.5)	25.3 (4.7)	27.4 (6.7)
Education (years)	10.5 (2.2)	10.8 (2.0)	11.3 (2.4)	11.4 (2.6)
Offspring variables				
Year of birth	1962.2 (1.9)	1963.0 (1.9)	1962.7 (1.8)	1962.8 (2.0)

AP, Affective psychoses; S.D., standard deviation.

[a] Cases *versus* controls (categorical variables). Compared with male controls, among male SCZ cases there were more African-Americans ($\chi^2_2=9.49$, $p=0.002$), single mothers ($\chi^3_2=6.77$, $p=0.03$) and participants from Providence ($\chi^1_2=3.94$, $p<0.05$). Among the categorical variables, there were no differences between female cases and controls.

[b] Cases *versus* controls (continuous/count variables): there were no significant differences between cases and controls by sex among the continuous variables.

(2004*b*) reported higher levels of maternal TNF-α and IL-8 respectively, in cases with psychoses compared with controls. The inconsistency of our findings with those previous findings may result, in part, from the lack of sample stratification by psychosis subtype and the inclusion of non-psychotic cases within the SCZ spectrum (e.g. schizotypal personality disorder) (Brown *et al.* 2004*b*). Furthermore, partly because of sample size, neither previous study tested for sex effects. In addition, the timing of sample acquisition differed in both previous studies (delivery, Buka *et al.* 2001*b*; second trimester, Brown *et al.* 2004*b*), possibly resulting in differential impact of gestational immune markers (Meyer *et al.* 2006; Aguilar-Valles & Luheshi, 2011), and as a function of sex (Goldstein & Walder, 2006). The difference in gestational timing of the sera draws is an important point as the maternal immune system exhibits considerable fluctuation during the course of pregnancy (Sargent, 1992). In Buka *et al.* (2001*b*), term levels of TNF-α were significantly greater among psychotic cases (predominately male) compared with controls. However, among male SCZ in

Table 2. *Differences in cytokine levels (in pg/ml) between SCZ cases and controls by sex using non-parametric methods*[a]

	Males			Females		
	SCZ ($n=34$)	Controls ($n=48$)	p value (non-parametric, Hochberg)	SCZ ($n=10$)	Controls ($n=52$)	p value (non-parametric, Hochberg)
IL-10						
Median	2.73	2.12	0.08	1.15	2.14	0.20
Mean	7.81	2.88	0.32	7.66	3.94	0.60
S.D.	17.52	3.16		15.75	5.07	
IL-1β						
Median	2.55	1.00	0.16	0.87	0.70	0.86
Mean	8.91	5.27	0.48	18.43	3.50	0.86
S.D.	11.31	10.48		48.71	5.46	
IL-8						
Median	14.91	15.25	0.39	30.57	16.27	0.84
Mean	46.24	116.35	0.78	81.92	69.34	0.86
S.D.	92.46	387.06		134.06	111.53	
IL-6						
Median	2.81	1.06	0.01	2.12	1.53	0.16
Mean	12.74	3.74	0.052	13.94	6.37	0.60
S.D.	16.66	7.98		29.70	17.43	
TNF-α						
Median	3.74	3.73	0.78	1.79	3.86	0.03
Mean	4.60	4.09	0.78	2.80	4.12	0.15[b]
S.D.	2.77	2.08		2.82	2.32	

SCZ, Schizophrenia psychoses; IL, interleukin; TNF, tumor necrosis factor; S.D., standard deviation.

[a] Comparisons between cases and controls made with the non-parametric Wilcoxon test using the ln transformed cytokine values. The Wilcoxon rank-sum test investigates differences in medians, with the assumption of identical spreads. If the two populations differed in spread using the Ansari–Bradley test, the more generalized Kolmogorov–Smirnov test was used. Tests assume observations from both groups are independent of each other; however, intrafamilial correction adjustment not made.

[b] Comparisons between cases and controls for individual cytokines, $p \leqslant 0.20$ after using the Hochberg method of adjustment for multiple comparisons.

the current study, where samples were drawn at the early third trimester, TNF-α levels were similar to those among controls. Comparing term sample assays with samples from the early third trimester, we found that the mean TNF-α levels from the former samples were elevated above those reported from the latter, particularly among the cases. The mean TNF-α level among mothers of SCZ males was 34% higher at term than at early third trimester (6.18 pg/ml *v.* 4.60 pg/ml) whereas the mean level among controls was 10% higher (4.57 pg/ml *v.* 4.09 pg/ml).

IL-6, a regulator of white matter growth, can enter the fetal brain during a key period of sexual differentiation (Dahlgren *et al.* 2006). Altered IL-6 levels found in the brain tissue of male, but not female, rat offspring as a result of hypothyroxinemia prompted by prenatal insult with polychlorinated biphenyls (PCBs) are associated with sex-specific alterations in

cerebellar white matter proteins (Miller *et al.* 2010). Furthermore, in response to lipopolysaccharide (LPS) stimulation, blood from human male fetuses revealed a pro-inflammatory response of elevated IL-6 concentrations not found in females (Kim-Fine *et al.* 2012). However, in response to mild maternal asthma, placental levels of IL-6 were significantly, and only, elevated among the female fetuses (Scott *et al.* 2009). Animal models have also established that injection of pregnant mice with IL-6 alters offspring behavior and cortical brain development, although specificity by offspring sex has not been examined. When administered in late second trimester in animal models of psychosis, IL-6, IL-1β and TNF-α reduced the number and length of frontal cortical dendrites (Marx *et al.* 2001; Gilmore *et al.* 2004) and induced deficits in prepulse and latent inhibitions (Zuckerman & Weiner, 2003; Smith *et al.* 2007*b*). Likewise, mimicking infection in pregnant

Table 3. *Differences in third trimester cytokine levels between (a) SCZ cases and (b) AP cases and controls by sex using multivariate deviant subgroup analysis*[a]

	Males						Females					
	Deviant subgroup, *n* (%)						Deviant subgroup, *n* (%)					
	Cases	Controls	χ^{2b}	*p* value	OR (95% CI)	*p* value	Cases	Controls	χ^{2b}	*p* value	OR (95% CI)	*p* value
(*a*) SCZ cases *versus* controls												
Deviant subgroup: highest quartile (top 75th percentile)												
IL-6	16 (47)	11 (23)	4.97	0.03*	3.33 (1.13–9.82)	0.03*	3 (33)	13 (27)		0.70	1.40 (0.30–6.57)	0.67
Deviant subgroup: lowest quartile (lowest 25th percentile)												
TNF-*α*	9 (26)	12 (26)	0.01	0.92	1.26 (0.42–3.81)	0.68	7 (70)	12 (23)		0.01*	6.30 (1.20–33.04)	0.03*
(*b*) AP cases *versus* controls												
Deviant subgroup: highest quartile (top 75th percentile)												
IL-6	5 (28)	11 (23)		0.75	0.98 (0.23–4.14)	0.98	4 (16)	13 (27)		0.39	0.54 (0.15–1.96)	0.35
Deviant subgroup: lowest quartile (lowest 25th percentile)												
TNF-*α*	6 (33)	12 (26)	0.40	0.53	1.33 (0.41–4.35)	0.63	10 (40)	12 (23)	2.37	0.12	2.16 (0.73–6.37)	0.16

SCZ, Schizophrenia psychoses; AP, affective psychoses; OR, odds ratio; CI, confidence interval; IL, interleukin; TNF, tumor necrosis factor; S.D., standard deviation.

[a] For those case *versus* control comparisons in which a difference of $p \leqslant 0.20$ was observed using non-parametric methods adjusted for multiple comparisons. Comparisons between cases and controls using multivariate deviant subgroup analyses at the 75th (IL-6) or 25th (TNF-*α*) percentile of the control ln transformed levels (referent) conducted using the generalized estimating equation (GEE) method, adjusted for intrafamilial correlation and demographic variables for which there were significant differences by (*a*) SCZ or (*b*) AP status and sex. For the male-specific analyses, these demographic variables were ethnicity, marital status and study site. There were no significant differences between female cases and controls on any of the potential confounding variables examined.

[b] χ^2 used to compare groups by deviant subgroup status. For those comparisons in which there were cells with $\leqslant 5$ subjects, Fisher's exact test was used.

* $p \leqslant 0.05$.

3256 J. M. Goldstein et al.

Table 4. *Differences in third-trimester cytokine levels between psychoses subtypes (SCZ and AP) by sex using multivariate deviant subgroup analysis[a]*

	Males						Females					
	Deviant subgroup n (%)						Deviant subgroup n (%)					
	SCZ	AP	χ^{2b}	p value	OR (95% CI)	p value	SCZ	AP	Fisher's exact	p value	OR (95% CI)	p value
IL-6	16 (47)	5 (28)	0.24		2.04 (0.52–7.94)	0.30	3 (33)	4 (16)		0.35	2.66 (0.46–15.46)	0.28
TNF-α	9 (26)	6 (33)	0.27	0.60	0.78 (0.18–3.42)	0.74	7 (70)	10 (40)		0.15	4.01 (0.72–22.2)	0.11

SCZ, Schizophrenia psychoses; AP, affective psychoses; OR, odds ratio; CI, confidence interval; IL, interleukin; TNF, tumor necrosis factor; s.d., standard deviation.

[a] For those case *versus* control comparisons in which a difference of $p \leqslant 0.20$ was observed using non-parametric methods adjusted for multiple comparisons. Comparisons between SCZ and AP using multivariate deviant subgroup analyses at the 75th (IL-6) or 25th (TNF-α) percentile of the control ln transformed levels (referent) conducted using the generalized estimating equation (GEE) method, adjusted for intrafamilial correlation and demographic variables for which there were significant differences by case status and sex. For the male-specific analyses, these demographic variables were ethnicity, marital status and study site. There were no significant differences between female cases and controls on any of the potential confounding variables examined.

[b] χ^2 used to compare groups by deviant subgroup status. For those comparisons in which there were cells with ⩽5 subjects, Fisher's exact test was used.

rodents through peripheral introduction of poly I:C, or LPS, had lasting offspring effects, such as increased levels of IL-6 in amniotic fluid and placenta (Urakubo *et al.* 2001; Gilmore *et al.* 2003), reduced neurogenesis (De Miranda *et al.* 2010) and behavioral deficits in offspring (Zuckerman & Weiner, 2003; De Miranda *et al.* 2010). Administration of non-steroidal anti-inflammatory drugs abrogated the effects of prenatal poly I:C on offspring neurogenesis and behavior (De Miranda *et al.* 2010). Rodent studies demonstrated specific effects of gestational IL-6 injection on offspring memory/working memory circuitry (Sparkman *et al.* 2006), deficits found in SCZ, particularly in men (Goldstein *et al.* 1998; Abbs *et al.* 2011), and that may be related to prenatal infection (Brown *et al.* 2009).

Animal studies are consistent with clinical studies demonstrating higher adult IL-6 levels in SCZ compared to healthy controls (Behrens & Sejnowski, 2009; Patterson, 2009; Watanabe *et al.* 2010). Effect sizes of IL-6 in acutely relapsed and first-episode patients were comparable and associated with longer illness duration (Ganguli *et al.* 1994) and paranoid hallucinations (Müller *et al.* 1997), and reduced by antipsychotic treatment (Sugino *et al.* 2009; Mutlu *et al.* 2012). Population studies, including the current one, demonstrated that fetal exposure to cytokines, as reflected by levels detected in maternal gestational sera, had a significant impact on sex-dependent SCZ risk, underscoring the etiologic contribution of immune processes prior to illness onset.

Our finding of lower maternal TNF-α in maternal prenatal sera of female offspring with SCZ, but not in males, was unexpected but intriguing. TNF-α has neuroprotective and neurotoxic effects on brain function (Twohig *et al.* 2011), and decreased levels could result from an increased glucocorticoid response due to pregnancy complications or other stressful events. Gonadal hormone and metabolic factors during pregnancy could also affect TNF-α. High-dose estradiol treatment (at levels similar to pregnancy) reduced T-helper (Th)1 cytokines (including TNF-α), and shifted the balance toward a Th2 anti-inflammatory state (Correale *et al.* 1998), whereas increased TNF-α was seen with low-dose estradiol exposure. Perhaps a maternal TNF-α deficit (in the context of a higher estradiol pregnant state) is further enhanced in mothers carrying a female *versus* male fetus, resulting in higher risk for SCZ in females associated with low maternal TNF-α. Lower maternal TNF-α was also associated with a higher mean glycemic index during the third trimester, implicating a potential role for metabolic pathways during pregnancy (Moreli *et al.* 2012). Reduced maternal TNF-α levels could also result from dysregulation of the parasympathetic autonomic nervous system (ANS) following immune challenge.

Nicotinic cholinergic signals transmitted by the vagus nerve to the central nervous system (CNS) after LPS (endotoxin) exposure inhibited TNF-α responses (Borovikova *et al.* 2000) and decreased TNF-α-mediated neuroprotection (Carlson *et al.* 1999). Consistent with this, abnormal patterns of autonomic arousal during social cognition tasks were reported in SCZ (Jáuregui *et al.* 2011). Female offspring of mothers who smoked during pregnancy might be dually affected by nicotine exposure, with effects through nicotine's capacity to drive vagal inhibition of TNF-α (thereby decreasing neuroprotective mechanisms), and through the more direct (perhaps sex-dependent) effects of nicotine on developing cholinergic brain circuitry (Nunes-Freitas *et al.* 2011). It is likely that multiple mechanisms regulate the effects of cytokines on offspring brain development, with specific mechanisms depending on timing of exposure. These include: dysregulation of nerve growth factors (Schobitz *et al.* 1993; Anisman & Merali, 2002; Gilmore *et al.* 2003; Twohig *et al.* 2011); loss of dendritic connections (Marx *et al.* 2001; Gilmore *et al.* 2004; Twohig *et al.* 2011) and white matter connectivity (Yoon *et al.* 1996; Dammann & Leviton, 1997); apoptosis (Hu *et al.* 1997); dysregulation of neurotransmitters (Zalcman *et al.* 1994; Behrens *et al.* 2008); and hormonal dysregulation (Schobitz *et al.* 1993; Anisman & Merali, 2002) impeding healthy sexual differentiation of the brain (Handa *et al.* 1994; Kawata, 1995; Tobet & Hanna, 1997; Goldstein *et al.* 2001; Tobet, 2002) and brain aging (Zietz *et al.* 2001).

It should be emphasized that our findings of sex-differentiated relationships between maternal immune activation signals and SCZ risk are based on comparisons within a sample set subjected to identical handling conditions. However, samples were frozen for up to 48 years, raising the possibility of sample dehydration or degradation. Dehydration was unlikely given that we eliminated any samples coming from tubes that were cracked or had faulty seals. Although some cytokines may be less stable than others, previous work using samples stored under similar conditions, and for a similar length of time (>40 years) (Stroud *et al.* 2007; Klebanoff *et al.* 2009), demonstrated long-term stability of many analytes. To ensure comparability of samples across all recruitment years (1959–1966), we also ruled out any relationship of cytokine levels with sample acquisition year (Spearman's correlation all <0.1). Assay controls (purchase of all reagents from the same lot and completion of all assays within the same 2-month period) served to further minimize potential sources of variability in cytokine measurements. Given the range of procedural safeguards we used with this sample set, in addition to excluding all cytokine values below the level of detection, the unexpected finding of an association of SCZ risk with lower TNF-α levels in female offspring cannot be explained by differential sample handling or artifacts of assay methods. The fact that there was a sex difference in risk due to lower TNF-α levels supports the validity of the assay measurement as it is highly unlikely that there would be a bias in maternal assay measurement by sex of the fetus. Similarly, our finding of an association of SCZ risk with elevated IL-6 levels, particularly in males, is also independent of effects due to differences in sample handling or assay conditions across the sample set.

The findings regarding specificity by sex or psychosis type should be replicated, given our small sample sizes, particularly female SCZ. In fact, IL-6 was higher in female SCZ cases, but not significantly, which may be due to low power. This may also have been true for IL-1β for which all cases showed higher levels (albeit non-significantly) than controls. TNF-α was also lower (non-significantly) in AP females *versus* controls. These results were not significant probably because of the substantial standard deviations and lower effect sizes compared with SCZ females. Potential low statistical power, however, cannot explain the significant risks for increased maternal IL-6 exposure among SCZ males and decreased maternal TNF-α exposure among SCZ females, even though the specificity of these effects should be further tested. As described in the online Supplementary material, based on analyses of the considerable amount of information available from this longitudinal study, it does not seem that the ascertained cases differ considerably from expectations, for instance in terms of gender distribution, socio-economic level or family history of mental illness, even though we had a low rate overall. Therefore, we anticipate that these study results should be generalizable to other psychotic samples and populations.

Several genes implicated in SCZ are also known to regulate immune processes (Carter, 2009). Infection and other factors disrupting maternal prenatal immune responses may interact with genetic susceptibility, increasing risk for SCZ (Patterson, 2009; Brown & Derkits, 2010). For example, gestational injection of IL-6 into pregnant IL-6 receptor knockout (KO) mice, or wild-type mice with an antibody directed against IL-6, did not induce behavioral changes typically observed after prenatal poly I:C injection (Smith *et al.* 2007*b*). Neurogenesis and behavior also remained intact in offspring of toll-like receptor (TLR)-3 KO dams after poly I:C exposure (De Miranda *et al.* 2010). Furthermore, cytokine production after infection or immune challenge may not be limited to the pregnant mother, as placental levels of IL-6 were increased after poly I:C administration to IL-6 KO mated with a

wild-type father, suggesting that poly I:C reached the fetal component of the placental unit (Mandal *et al.* 2010).

In summary, the findings in this study demonstrate that prenatal immune disturbances in the early third trimester significantly increased the risk for psychoses in a sex-dependent manner more than 40 years later. Male offspring were most strongly affected by maternal IL-6 elevations; female offspring were affected when maternal TNF-α levels were lower. The results underscore the importance of immunologic processes in brain development and timing of exposure (i.e. timing of the sexual differentiation of the brain) as potential etiologic contributors to the sex-dependent development of SCZ. The findings also highlight the importance of considering the type of psychosis and offspring sex in the study design to improve our understanding of the gestational impact of immunologic processes on psychosis risk. Finally, our findings may have implications for other neurodevelopmental disorders, given the report by Hsiao *et al.* (2012) on prenatal immunologic processes implicated in the risk for autism, which has a 4:1 ratio of boys to girls (Yeargin-Allsopp *et al.* 2003).

Supplementary material

For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291714000683.

References

Abbs B, Liang L, Makris N, Tsuang MT, Seidman LJ, Goldstein JM (2011). Covariance modeling of MRI brain volumes in memory circuitry in schizophrenia: sex differences are critical. *NeuroImage* **56**, 1865–1874.

Aguilar-Valles A, Luheshi GN (2011). Alterations in cognitive function and behavioral response to amphetamine induced by prenatal inflammation are dependent on the stage of pregnancy. *Psychoneuroendocrinology* **36**, 634–648.

Anisman H, Merali Z (2002). Cytokines, stress, and depressive illness. *Brain, Behavior, and Immunity* **16**, 513–524.

Behrens MM, Ali SS, Dugan LL (2008). Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. *Journal of Neuroscience* **28**, 13957–13966.

Behrens MM, Sejnowski TJ (2009). Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? *Neuropharmacology* **57**, 193–200.

Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* **405**, 458–462.

Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP, Susser ES (2004*a*). Serologic evidence of prenatal influenza in the etiology of schizophrenia. *Archives of General Psychiatry* **61**, 774–780.

Brown AS, Derkits EJ (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. *American Journal of Psychiatry* **167**, 261–280.

Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES (2004*b*). Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. *American Journal of Psychiatry* **161**, 889–895.

Brown AS, Vinogradov S, Kremen WS, Poole JH, Deicken RF, Penner JD, McKeague IW, Kochetkova A, Kern D, Schaefer CA (2009). Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. *American Journal of Psychiatry* **166**, 683–690.

Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH (2001*a*). Maternal infections and subsequent psychosis among offspring: a forty year prospective study. *Archives of General Psychiatry* **58**, 1032–1037.

Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH (2001*b*). Maternal cytokine levels during pregnancy and adult psychosis. *Brain, Behavior, and Immunity* **15**, 411–420.

Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC (1999). Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. *Journal of Immunology* **163**, 3963–3968.

Carter CJ (2009). Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and *Toxoplasma gondii*. *Schizophrenia Bulletin* **35**, 1163–1182.

Castle DJ, Wessely S, Murray RM (1993). Sex and schizophrenia: effects of diagnostic stringency, and associations with premorbid variables. *British Journal of Psychiatry* **162**, 653–664.

Correale J, Arias M, Gilmore W (1998). Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. *Journal of Immunology* **161**, 3365–3374.

Dahlgren J, Samuelsson AM, Jansson T, Holmäng A (2006). Interleukin-6 in the maternal circulation reaches the rat fetus in mid-gestation. *Pediatric Research* **60**, 147–151.

Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M (1999). Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. *Archives of General Psychiatry* **56**, 234–240.

Dammann O, Leviton A (1997). Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. *Pediatric Research* **42**, 1–8.

De Miranda J, Yaddanapudi K, Hornig M, Villar G, Serge R, Lipkin WI (2010). Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances. *MBio* **1**, e00176–10.

Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, Drexhage HA (2010). The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. *Expert Review of Neurotherapeutics* **10**, 59–76.

Eide M, Moster D, Irgens L, Reichborn-Kjennerud T, Stoltenberg C, Skjærven R, Susser E, Abel K (2013). Degree of fetal growth restriction associated with schizophrenia risk in a national cohort. *Psychological Medicine* **43**, 2057–2066.

Elenkov IJ (2008). Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. *Neurochemistry International* **52**, 40–51.

Faraone SV, Tsuang MT (1985). Quantitative models of the genetic transmission of schizophrenia. *Psychological Bulletin* **98**, 41–66.

Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi A, Rabin BS (1994). Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. *Psychiatry Research* **51**, 1–10.

Gilmore JH, Jarskog LF (1997). Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. *Schizophrenia Research* **24**, 365–367.

Gilmore JH, Jarskog LF, Vadlamudi S (2003). Maternal infection regulates BDNF and NGF expression in fetal and neonatal brain and maternal-fetal unit of the rat. *Journal of Neuroimmunology* **138**, 49–55.

Gilmore JH, Jarskog LF, Vadlamudi S, Lauder JM (2004). Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. *Neuropsychopharmacology* **29**, 1221–1229.

Goldstein JM, Buka SL, Seidman LJ, Tsuang MT (2010). Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design. *Archives of General Psychiatry* **67**, 458–467.

Goldstein JM, Cherkerzian S, Seidman LJ, Petryshen TL, Fitzmaurice G, Tsuang MT, Buka SL (2011). Sex-specific rates of transmission of psychosis in the New England high-risk family study. *Schizophrenia Research* **128**, 150–155.

Goldstein JM, Seidman LJ, Goodman JM, Koren D, Lee H, Weintraub S, Tsuang MT (1998). Are there sex differences in neuropsychological functions among patients with schizophrenia? *American Journal of Psychiatry* **155**, 1358–1364.

Goldstein JM, Seidman LJ, Horton NJ, Makris N, Kennedy DN, Caviness VS Jr., Faraone SV, Tsuang MT (2001). Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. *Cerebral Cortex* **11**, 490–497.

Goldstein JM, Walder DJ (2006). Sex differences in schizophrenia: the case for developmental origins and etiological implications. In *The Early Course of Schizophrenia* (ed. T. Sharma and P. D. Harvey), pp. 147–173. Oxford University Press: Oxford, UK.

Gottesman II (1991). *Schizophrenia Genesis: The Origin of Madness*. W.H. Freeman and Company: New York.

Handa RJ, Burgess LH, Kerr JE, O'Keefe JA (1994). Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. *Hormones and Behavior* **28**, 464–476.

Harbuz MS, Stephanou A, Sarlis N, Lightman SL (1992). The effects of recombinant human interleukin (IL)-1 alpha, IL-1 beta or IL-6 on hypothalamo-pituitary-adrenal axis activation. *Journal of Endocrinology* **133**, 349–355.

Hochberg Y (1988). A sharper Bonferroni procedure for multiple tests of significance. *Biometrika* **75**, 800–802.

Hornig M (2013). The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. *Current Opinion in Rheumatology* **25**, 488–795.

Hornig M, Weissenbock H, Horscroft N, Lipkin WI (1999). An infection-based model of neurodevelopmental damage. *Proceedings of the National Academy of Sciences USA* **96**, 12102–12107.

Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH (2012). Modeling an autism risk factor in mice leads to permanent immune dysregulation. *Proceedings of the National Academy of Sciences USA* **109**, 12776–12781.

Hu Z, Yuri K, Ozawa H, Lu H, Kawata M (1997). The in vivo time course for elimination of adrenalectomy-induced apoptotic profiles from the granule cell layer of the rat hippocampus. *Journal of Neuroscience* **17**, 3981–3989.

Jáuregui OI, Costanzo EY, de Achával D, Villarreal MF, Chu E, Mora MC, Vigo DE Castro MN, Leiguarda RC, Bär KJ, Guinjoan SM (2011). Autonomic nervous system activation during social cognition tasks in patients with schizophrenia and their unaffected relatives. *Cognitive and Behavioral Neurology* **24**, 194–203.

Kawata M (1995). Roles of steroid hormones and their receptors in structural organization in the nervous system. *Neuroscience Research* **24**, 1–46.

Kendler KS, Gruenberg AM, Tsuang MT (1985). Subtype stability in schizophrenia. *American Journal of Psychiatry* **142**, 827–832.

Kim-Fine S, Regnault TR, Lee JS, Gimbel SA, Greenspoon JA, Fairbairn J, Summers K, de Vrijer B (2012). Male gender promotes an increased inflammatory response to lipopolysaccharide in umbilical vein blood. *Journal of Maternal-Fetal and Neonatal Medicine* **25**, 2470–2474.

Klebanoff MA, Zhang J, Zhang C, Levine RJ (2009). Maternal serum theobromine and the development of preeclampsia. *Epidemiology and Community Health* **20**, 727–732.

Mandal M, Marzouk AC, Donnelly R, Ponzio NM (2010). Preferential development of Th17 cells in offspring of immunostimulated pregnant mice. *Journal of Reproductive Immunology* **87**, 97–100.

Martins TB (2002). Development of internal controls for the Luminex instrument as part of a multiplex seven-analyte viral respiratory antibody profile. *Clinical and Diagnostic Laboratory Immunology* **9**, 41–45.

Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001). Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. *Biological Psychiatry* **50**, 743–749.

McGrath J, Murray R (2003). Risk factors for schizophrenia: from conception to birth. In *Schizophrenia* (ed. S. R. Hirsh and D. R. Weinberger), pp. 232–250. Blackwell Science: Malden, MA.

Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J (2006). The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. *Journal of Neuroscience* **26**, 4752–4762.

Miller V, Kahnke T, Neu N, Sanchez-Morrissey S, Brosch K, Kelsey K, Seegal R (2010). Developmental PCB exposure induces hypothyroxinemia and sex-specific effects on cerebellum glial protein levels in rats. *International Journal of Developmental Neuroscience* **28**, 553–560.

Moreli JB, Morceli G, De Luca AK, Magalhães CG, Costa RA, Damasceno DC, Rudge MV, Calderon IM (2012). Influence of maternal hyperglycemia on IL-10 and TNF-α production: the relationship with perinatal outcomes. *Journal of Clinical Immunology* **32**, 604–610.

Müller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil M (1997). Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. *European Psychiatry* **12**, 294–299.

Mutlu O, Gumuslu E, Ulak G, Celikyurt IK, Kokturk S, Kir HM, Akar F, Erden F (2012). Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice. *Life Sciences* **91**, 1252–1262.

Niswander KR, Gordon M (1972). *The Collaborative Perinatal Study of the National Institute of Neurological Diseases and Stroke: The Women and Their Pregnancies.* Government Printing Office, U.S. Department of Health, Education, and Welfare: Washington, DC.

Nunes-Freitas AL, Ribeiro-Carvalho A, Lima CS, Dutra-Tavares AC, Manhães AC, Lisboa PC, Oliveira E, Gaspar de Moura E, Filgueiras CC, Abreu-Villaça Y (2011). Nicotine exposure during the third trimester equivalent of human gestation: time course of effects on the central cholinergic system of rats. *Toxicological Sciences* **123**, 144–154.

O'Connell P, Woodruff PW, Wright I, Jones P, Murray RM (1997). Developmental insanity or dementia praecox: was the wrong concept adopted? *Schizophrenia Research* **23**, 97–106.

Patterson PH (2007). Maternal effects on schizophrenia risk. *Science* **318**, 576–577.

Patterson PH (2009). Immune involvement in schizophrenia and autism: etiology, pathology and animal models. *Behavioral Brain Research* **204**, 313–321.

Sargent I (1992). Maternal and fetal immune responses during pregnancy. *Experimental and Clinical Immunogenetics* **10**, 85–102.

Schobitz B, de Kloet ER, Sutanto W, Holsboer F (1993). Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. *European Journal of Neuroscience* **5**, 1426–1435.

Scott NM, Hodyl NA, Murphy VE, Osei-Kumah A, Wyper H, Hodgson DM, Smith R, Clifton VL (2009). Placental cytokine expression covaries with maternal asthma severity and fetal sex. *Journal of Immunology* **182**, 1411–1420.

Seckl JR (2001). Glucocorticoid programming of the fetus: adult phenotypes and molecular mechanisms. *Molecular and Cellular Endocrinology* **185**, 61–71.

Seckl JR, Walker BR (2001). Minireview: 11beta-hydroxysteroid dehydrogenase type 1 – a tissue-specific amplifier of glucocorticoid action. *Endocrinology* **142**, 1371–1376.

Seidman LJ, Cherkerzian S, Goldstein JM, Agnew-Blais J, Tsuang MT, Buka SL (2013). Neuropsychological performance and family history in children at age 7 who develop adult schizophrenia or bipolar psychosis in the New England Family Studies. *Psychological Medicine* **43**, 119–131.

Smith AJ, Li M, Becker S, Kapur S (2007*a*). Linking animal models of psychosis to computational models of dopamine function. *Neuropsychopharmacology* **32**, 54–66.

Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007*b*). Maternal immune activation alters fetal brain development through interleukin-6. *Journal of Neuroscience* **27**, 10695–10702.

Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW (2006). Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. *Journal of Neuroscience* **26**, 10709–10716.

Stratton MS, Searcy BT, Tobet SA (2011). GABA regulates corticotropin releasing hormone levels in the paraventricular nucleus of the hypothalamus in newborn mice. *Physiology and Behavior* **104**, 327–333.

Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL (2007). Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. *Psychoneuroendocrinology* **32**, 140–150.

Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y (2009). Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **33**, 303–307.

Szelenyi J, Vizi ES (2007). The catecholamine cytokine balance: interaction between the brain and the immune system. *Annals of the New York Academy of Sciences* **1113**, 311–324.

Tobet SA (2002). Genes controlling hypothalamic development and sexual differentiation. *European Journal of Neuroscience* **16**, 373–376.

Tobet SA, Hanna IK (1997). Ontogeny of sex differences in the mammalian hypothalamus and preoptic area. *Cellular and Molecular Neurobiology* **17**, 565–601.

Tsuang MT, Faraone SV, Lyons MJ (1993). Identification of the phenotype in psychiatric genetics. *European Archives of Psychiatry and Clinical Neuroscience* **243**, 131–142.

Twohig JP, Cuff SM, Yong AA, Wang EC (2011). The role of tumor necrosis factor receptor superfamily members in mammalian brain development, function and homeostasis. *Reviews in the Neurosciences* **22**, 509–533.

Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH (2001). Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. *Schizophrenia Research* **47**, 27–36.

Vignali DA (2000). Multiplexed particle-based flow cytometric assays. *Journal of Immunological Methods* **243**, 243–255.

Watanabe Y, Someya T, Nawa H (2010). Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. *Psychiatry and Clinical Neurosciences* **64**, 217–230.

Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C (2003). Prevalence of autism in a US metropolitan area. *Journal of the American Medical Association* **289**, 49–55.

Yoon BH, Romero R, Yang SH, Jun JK, Kim IO, Choi JH, Syn HC (1996). Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. *American Journal of Obstetrics and Gynecology* **174**, 1433–1440.

Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH (1994). Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. *Brain Research* **643**, 40–49.

Zietz B, Hrach S, Scholmerich J, Straub RH (2001). Differential age-related changes of hypothalamus-pituitary-adrenal axis hormones in healthy women and men – role of interleukin 6. *Experimental and Clinical Endocrinology and Diabetes* **109**, 93–101.

Zuckerman L, Weiner I (2003). Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. *Psychopharmacology (Berlin)* **169**, 308–313.